Share this article
Share this article
RADNOR, Pa., May 25, 2021 /PRNewswire/ -- Today, NeuroRx, Inc., announced it has been approved by the Nasdaq for listing on the Nasdaq Global Market, following the completion of its business combination with Big Rock Partners Acquisition Corp. (Nasdaq:BRPA). The combined entity is NRx Pharmaceuticals, Inc. and will trade on the Nasdaq Global Market as NRXP.
"Today marks a major milestone as we include public investors in our quest to bring innovative medicines to patients at immediate risk of death, who have no currently-approved medicinal therapies. We live by our credo of "Bringing Hope to Life," said Professor Jonathan Javitt, MD, MPH, Founder, CEO and Chairman of the Board, of NRx. "We are indebted to the leaders and shareholders of BRPA who have chosen to support our mission."